Claude Science Focuses on Research Workflows Instead of a New AI Model Artificial intelligence is becoming a bigger part of scientific research, but many researchers still struggle to fit AI into their daily work. Anthropic's Claude Science is designed to solve that challenge. Instead of launching another powerful AI model, the company is focusing on improving research workflows, helping scientists organize information, analyze data, review literature, and accelerate discoveries. This strategy reflects a growing belief that better research tools can deliver more value than simply increasing model size. The move highlights an important shift in the AI industry. Rather than competing only on benchmark scores, AI companies are increasingly building specialized products that solve real-world problems. For scientists, that means AI assistants that understand how research is actually conducted.
Jeff Bezos’s Prometheus Raises $12 Billion to Build an Artificial General Engineer for the Physical World A new chapter in artificial intelligence is unfolding as Prometheus secures a staggering $12 billion funding round to pursue one of the most ambitious goals in technology: creating an artificial general engineer. Unlike today’s AI systems that primarily generate text, images, or code, Prometheus aims to develop technology capable of understanding, designing, and improving real-world systems across industries. The investment signals growing confidence that AI could soon move beyond digital tasks and play a major role in shaping the physical world. The announcement has sparked excitement across technology, manufacturing, robotics, and infrastructure sectors, with many viewing the project as a potential turning point in the race toward advanced artificial intelligence.
Apple Health App Adds Perimenopause Support in Major Women’s Health Update Women searching for better ways to track perimenopause symptoms now have a new digital tool available through the Apple Health App. Announced during WWDC 2026, the latest update expands the app’s existing cycle tracking capabilities to include perimenopause and menopause support. The new features are designed to help users monitor symptoms, recognize changing cycle patterns, and access educational resources that can support conversations with healthcare professionals. The move reflects a growing global focus on women’s health and highlights how technology companies are investing more heavily in tools that address long-overlooked health needs.
H1 Secures $40M as Healthcare SaaS Defies AI Slowdown The AI investment boom has made life difficult for many traditional software startups, but healthcare data company H1 is proving that specialized SaaS businesses can still attract major investor attention. H1 recently secured $40 million in fresh funding from CVS Health Ventures, signaling continued confidence in healthcare-focused data platforms even as venture capital increasingly shifts toward artificial intelligence startups. The funding round arrives at a time when many investors are pulling back from older SaaS models. Companies that once dominated venture capital conversations are now competing against fast-growing AI startups commanding massive valuations and media attention. Yet H1’s latest raise suggests that businesses built around proprietary healthcare data may still hold a strong position in the evolving tech landscape.
Triomics AI is making a bold move in healthcare technology after raising $22 million to expand its oncology-focused artificial intelligence platform for cancer centers. The funding highlights a growing shift toward specialized AI systems designed for real clinical environments rather than general-purpose tools. As hospitals and cancer research institutions continue struggling with overwhelming patient data, staffing shortages, and complex treatment planning, oncology-specific AI is emerging as one of the healthcare industry’s most promising areas. Triomics AI wants to position itself at the center of that transformation by helping physicians, researchers, and healthcare providers streamline cancer care operations and clinical decision-making. The company’s latest funding round arrives at a time when healthcare organizations are actively searching for AI solutions that can improve efficiency without sacrificing patient outcomes. Investors are increasingly betting that focused medical AI …
Imperagen raises £5 million is making waves in biotech as the startup unveils a powerful fusion of quantum physics, artificial intelligence, and robotics to transform enzyme engineering. If you are searching for what Imperagen does, how its technology works, or why investors are betting on AI-driven biotech, the answer lies in its mission to replace slow, trial-and-error enzyme development with faster, computer-guided discovery. The company believes this shift could reshape pharmaceuticals, industrial chemistry, and sustainable manufacturing. At its core, Imperagen is targeting one of the most complex problems in modern science: designing enzymes that reliably perform specific chemical reactions. These enzymes are essential in drug development, food production, agriculture, and biofuels. By accelerating how enzymes are engineered, the company aims to reduce costs, shorten development timelines, and unlock new possibilities for bio-based industries.
Musely funding is making headlines after the telemedicine platform secured over $360 million without giving up equity—something many founders actively search for. Instead of traditional venture capital or bank loans, Musely partnered with General Catalyst through an alternative financing model that ties repayment to revenue. This approach could reshape how startups scale, especially in high-cost sectors like direct-to-consumer healthcare. Musely Secures $360M Without Equity Dilution In a startup ecosystem where equity is often traded for growth, Musely has taken a different path. The company raised over $360 million in non-dilutive capital from General Catalyst’s Customer Value Fund (CVF). Unlike traditional venture capital, this funding does not require founders to give up ownership stakes in their company. This is a significant shift from the usual startup playbook. Most high-growth companies rely heavily on venture funding rounds that dilute founder ownership over time. Musely’s appro…
WHAT THE SCIENCE CORP BRAIN SENSOR HUMAN TRIAL MEANS The Science Corp brain sensor human trial is generating intense interest in the neuroscience and biotech world as the company moves closer to testing its first brain-computer interface in humans. Many people searching for this breakthrough want to know whether it is safe, when trials will begin, and what it could mean for conditions like blindness, paralysis, and Parkinson’s disease. At its core, this development involves a biohybrid brain sensor designed to sit on the surface of the brain and communicate with both electronics and living neurons. The goal is not only to restore lost neurological functions but also to explore future possibilities of enhanced human cognition. Backed by major funding and guided by leading neurosurgical experts, the project represents one of the most ambitious attempts yet to merge biology with computing.
Anthropic Acquires Coefficient Bio in a Shocking $400M Biotech Deal Anthropic has acquired Coefficient Bio, a stealth biotech AI startup, in a reported $400 million stock deal. The acquisition signals a dramatic acceleration of Anthropic's ambitions in healthcare and drug discovery, just months after the company launched its first dedicated life sciences product. If you have been watching the AI industry closely, this is a move you cannot afford to ignore. What Is Coefficient Bio and Why Does It Matter Coefficient Bio was not a household name, and that was entirely by design. Founded just eight months before the acquisition closed, the startup operated in stealth mode, quietly building AI tools aimed at making drug discovery and biological research faster and more efficient. Behind the company were two founders with serious credentials: Samuel Stanton and Nathan C. Frey. Both had worked at Genentech's Prescient Design, one of the most respected computational drug discovery units i…
Fitness Tech Merger Creates a $7.5B Wellness Giant — And It Changes Everything About How You Work Out The fitness industry just got a massive shakeup. Playlist — the company behind ClassPass, Mindbody, and Booker — has officially completed its merger with smart gym technology company EGYM, creating a combined entity valued at $7.5 billion. The deal, finalized on March 31, 2026, brings together gym software, consumer booking apps, AI-powered training tools, and corporate wellness benefits under one roof. If you use a gym, book fitness classes, or access wellness perks through your employer, this merger will likely touch your life sooner than you think. Why This Fitness Merger Is Unlike Anything We Have Seen Before Most fitness industry deals involve one company buying another. This merger is different in both scale and ambition. Playlist already operated three distinct brands — Mindbody, a software platform used widely by gyms and studios; ClassPass, a consumer app that lets members book …
What Are Digital Twins of Humans — and Why Does Medicine Need Them Now? Digital twins of humans are physics-based, AI-powered virtual models that replicate how a real person's body moves, responds, and behaves. They are built from real-world data — biometric readings, medical imaging, motion capture, and more. And right now, a New York-based startup called Mantis Biotech is using them to tackle one of medicine's most stubborn problems: the lack of reliable data for rare diseases, edge cases, and complex human conditions. The solution they have built is unlike anything the biomedical world has seen before. The promise of artificial intelligence in healthcare is enormous. Large language models could speed up genomics research, streamline clinical documentation, improve real-time diagnostics, and accelerate drug discovery. But time and again, these models hit the same wall — there simply is not enough high-quality, representative data to make them work in the cases that matter most…
Ultrahuman Ring Pro Is Back in the US — And the Smart Ring War Just Got Real The Ultrahuman Ring Pro has officially secured US clearance, and the Bengaluru-based health tech company is wasting no time. After months of painful import restrictions that wiped out tens of millions in revenue, Ultrahuman is relaunching in the most important smart ring market in the world — and it is walking straight into Oura's strengthened grip. Here is everything you need to know about what happened, what changed, and what comes next. Why Ultrahuman Was Blocked From the US in the First Place It was not a product failure that kept Ultrahuman out of the US market. It was a legal one. In October 2025, the US International Trade Commission ruled in favour of Oura in a patent dispute, effectively halting imports of Ultrahuman's Ring Air into the country. The fallout was severe. CEO Mohit Kumar confirmed the restrictions cost the company up to $50 million in lost sales during the period it was unable to s…
Brain-Computer Interface Startup Gestala Raises $21M in Record China BCI Round Chinese ultrasound brain-computer interface startup Gestala has secured $21.6 million in funding just two months after its founding — setting a new record for early-stage BCI investment in China. Founded by serial entrepreneur Phoenix Peng, Gestala is developing non-invasive brain-computer interfaces that could change how humans interact with technology, without the need for surgery. A Record-Breaking Round That Nobody Expected This Fast When a startup raises a nine-figure valuation within its first sixty days of existence, the industry takes notice. Gestala, valued between $100 million and $200 million, closed a CN¥150 million ($21.6 million) funding round co-led by Guosheng Capital and Dalton Venture. The round also attracted participation from Tsing Song Capital, Gobi Ventures, Fourier Intelligence, Liepin, and Seas Capital. What's even more striking is that investor demand far exceeded the raise itsel…
Healthcare administrative work is quietly crushing the medical industry — and Amazon Web Services just launched a product aimed directly at fixing it. Amazon Connect Health is a new AI agent-powered platform designed to help healthcare organizations automate repetitive administrative tasks: appointment scheduling, patient verification, clinical documentation, and more. The platform is HIPAA-eligible, integrates with electronic health record (EHR) software, and is already partnered with leading EHR providers, data integrators, and patient engagement companies. What Is Amazon Connect Health, Exactly? At its core, Amazon Connect Health is a cloud-based platform that deploys AI agents — software designed to complete complex workflows on behalf of a human — inside healthcare environments. Unlike basic automation tools, these agents can handle multi-step tasks like reviewing medical history, managing clinical documentation, and coordinating patient intake, all within a regulatory-compliant f…
A brain-computer interface startup co-founded by a former Neuralink executive just secured $230 million in new funding — and it may be closer to putting a product in patients' hands than anyone in the industry. Science Corporation, led by Max Hodak, is betting that a rice-grain-sized eye implant will make it the first BCI company to actually reach the market. Here's what you need to know. The $230 Million Bet on Brain-Computer Interface Technology Science Corporation announced Wednesday that it has closed a $230 million Series C funding round. According to a source close to the company, the round values Science Corp. at $1.5 billion post-money — a striking figure for a startup operating in one of biotech's most complex and competitive spaces. The brain-computer interface sector has long been viewed as a moonshot territory, drawing headlines but few concrete clinical results. While the broader venture capital world has spent the last two years chasing artificial intelligence …
Deepinder Goyal Temple: $54M Bet on Brain-Tech Future Just weeks after stepping down from Zomato, entrepreneur Deepinder Goyal is back—with a bold new venture. Temple, his brain-monitoring wearable startup, has secured $54 million in early funding. What exactly is Temple building? Why are top investors betting big? And how could this technology reshape how we interact with our devices? Here's what you need to know about Goyal's high-stakes pivot into neurotech. The $54M Friends-and-Family Round Behind Deepinder Goyal Temple Temple's initial funding round closed at a post-money valuation of approximately $190 million. The raise, structured as a friends-and-family round, drew participation from more than 30 employees who invested at the same valuation. This approach signals strong internal confidence in the venture's direction and Goyal's leadership. The capital injection positions Temple to accelerate research and development on its core technology: non-invasive wearabl…
Ultrahuman Ring Pro: Redesigned Smart Ring Targets US Return What is the Ultrahuman Ring Pro, and why does its launch matter for wearable tech fans? The newly unveiled smart ring promises up to 15 days of battery life, a redesigned form factor, and advanced health insights—all as Ultrahuman works to restore its U.S. presence following a high-profile patent dispute. If you're researching premium wearable rings in 2026, here's what you need to know about the Ring Pro's features, availability, and the legal backdrop shaping its rollout. Ultrahuman Ring Pro Specs and Design Upgrades The Ultrahuman Ring Pro represents a significant hardware evolution for the Bengaluru-based wearable maker. Building on feedback from earlier generations, the third-generation ring features a slimmer profile and refined ergonomics designed for all-day comfort. Battery life sees the most dramatic improvement, jumping from four to six days on the previous Ring Air model to an impressive 15 days on the Pr…
China Brain-Computer Interface Industry Surges Ahead What's driving China's rapid advancement in brain-computer interface technology? While global attention often focuses on Western pioneers, China's BCI industry is quietly transitioning from laboratory research to real-world commercialization. Backed by coordinated policy support, expanding clinical trials, and a new generation of specialized startups, the sector is positioning itself for multibillion-dollar growth within the next five years. This shift isn't just about treating neurological conditions—it's laying groundwork for future human-AI integration. Policy Support Accelerates BCI Commercialization in China China's national and provincial governments are actively creating pathways for BCI adoption. Provinces including Sichuan, Hubei, and Zhejiang have already established medical service pricing frameworks for brain-computer interface procedures. This critical step paves the way for inclusion in the nationa…
Longevity Million-Dollar Price Tag: Inside Bryan Johnson's Immortals Program What does a $1 million annual longevity program actually deliver? Bryan Johnson's newly launched "Immortals" service offers three ultra-high-net-worth individuals access to his complete five-year health protocol, featuring AI coaching, continuous biomarker tracking, and personalized medical interventions. The program represents the latest escalation in Silicon Valley's race to extend human healthspan—though experts caution that true age reversal remains unproven despite aggressive biohacking approaches. Credit: SXSW 2025 Johnson, the founder of payment platform Braintree, has spent years publicly documenting his "Blueprint" regimen: precise nutrition timing, rigorous exercise schedules, extensive supplementation, and frequent medical testing. Now he's productizing that experience for an exclusive clientele willing to invest seven figures annually in pursuit of extended vitalit…
AI Drug Discovery Solves Rare Disease Labor Crisis For years, biotech labs held the tools to edit genes and design precision medicines—yet over 7,000 rare diseases remain without approved treatments. The bottleneck wasn't technology. It was people. Now, AI drug discovery platforms are stepping in as force multipliers, letting small teams tackle diseases once deemed commercially unviable. At recent industry forums in Doha, leaders revealed how artificial intelligence is closing the talent gap—and bringing hope to millions of patients left behind. Credit: Web Summit The Human Bottleneck Behind Rare Disease Research Rare diseases affect fewer than 200,000 people each in the United States, but collectively impact 300 million globally. Developing treatments for these conditions demands deep expertise across genomics, protein chemistry, and clinical trial design. Yet pharmaceutical companies historically deprioritized them. Why? The math didn't work. Assembling specialized teams for ult…